 |
|
Screening for left ventricular dysfunction may have less value than thought
June 12, 2009The value and cost-effectiveness of screening for left ventricular (LV) dysfunction remains unclear, particularly since specific, evidence-based treatments are not available for the majority of patients with preserved systolic dysfunction, reports a study in the June issue of the Journal of Cardiac Failure (http://www.onlinejcf.com), published by Elsevier.
In the study,1012 primary care patients with hypertension and/or diabetes without signs or symptoms of heart failure were screened for asymptomatic left ventricular dysfunction (ALVD), using measurements of NT-pro-BNP and echocardiography. Diastolic dysfunction was found in 368 subjects (36%) and was categorized as mild in 327 and moderate-severe in 41. Systolic dysfunction was present in only 11 (1.1%)l. NT-proBNP levels were 170±206 and 859±661 pg/mL respectively in diastolic and systolic dysfunction and 92±169 in normal subjects (p<.0001).
For the 52 subjects (5.1%) with moderate to severe diastolic dysfunction or systolic dysfunction, a NT-proBNP of < 125 pg/ml had a negative predictive value (NPV) >99% and a positive predictive value of 33% in patients < 67 years. For older patients, NPV was 100%, but PPV was somewhat lower in women (23%) than in men (33%).
This study suggests that the evaluation of NT-proBNP in asymptomatic patients with type 2 diabetes or hypertension may lead to very early exclusion of LV dysfunction. As a perspective of this study, general practitioners could use NT-proBNP determination to rule out heart failure (HF) in these patients, a much more cost effective measure than the use of an echocardiographic one. The study was partially supported by an unrestricted grant from Roche Diagnostics.
"This study demonstrates that low values of NT-proBNP usually exclude significant LV dysfunction, but elevated values are relatively non-specific, especially in a population where systolic dysfunction is rare," comments Barry M. Massie, M.D., Editor-in-Chief of the Journal of Cardiac Failure.
Elsevier
This study suggests that the evaluation of NT-proBNP in asymptomatic patients with type 2 diabetes or hypertension may lead to very early exclusion of LV dysfunction. As a perspective of this study, general practitioners could use NT-proBNP determination to rule out heart failure (HF) in these patients, a much more cost effective measure than the use of an echocardiographic one. The study was partially supported by an unrestricted grant from Roche Diagnostics.
"This study demonstrates that low values of NT-proBNP usually exclude significant LV dysfunction, but elevated values are relatively non-specific, especially in a population where systolic dysfunction is rare," comments Barry M. Massie, M.D., Editor-in-Chief of the Journal of Cardiac Failure.
Elsevier
Systolic Dysfunction Current Events and Systolic Dysfunction News RSSSleep apnea may not be closely linked to heart failure severity
Obstructive sleep apnea (OSA) and central sleep apnea (CSA) are not markedly decreased in heart failure (HF) patients managed with beta-blockers and spironolactone.
Hidden heart condition increases the risk of death in patients waiting for kidney transplants
An often asymptomatic condition-systolic dysfunction, or decreased pumping of the heart-poses an increased risk of death for patients on kidney transplant waiting lists, according to a study appearing in the June 2008 issue of the Journal of the American Society Nephrology (JASN).
Metabolic syndrome points to heart health
Typified by high blood pressure, weight gain around the waist and problems regulating blood sugar, metabolic syndrome may also be associated with compromised heart structure and function.
Most hospital performance measures for heart failure not linked to improved patient outcomes
Four of five hospital performance measures for heart failure do not appear to accurately reflect the quality of care provided.
A simple, noninvasive test measures survival time in adult pulmonary hypertension
Researchers have developed a simple, noninvasive way to measure right ventricular function in the heart to predict survival of adults who suffer from pulmonary hypertension.
Amias® (candesartan cilexetil), an antihypertensive drug, now shows clear benefits in symptomatic heart failure
Amias® (candesartan cilexetil), an antihypertensive drug, now shows clear benefits in symptomatic heart failure CHARM Study Programme demonstrates that Amias® saves lives and reduces hospitalisation in heart failure, irrespective of background therapy European Society of Cardiology, Vienna, 31st August 2003 - Exciting results from the largest study of an angiotensin receptor blocker (ARB) in the treatment of heart failure - the CHARM (Candesartan in Heart failure - Assessment of Reduction in Mortality and morbidity) Study Programme - were presented today revealing that Amias (candesartan cilexetil) reduces cardiovascular deaths and hospital admissions, irrespective of background therap
HEART FAILURE UNDERDIAGNOSED IN UK PRIMARY CARE (pp 432, 439)
A UK study published in this week’s issue of THE LANCET suggests that heart failure is more common than previously thought. New strategies involving the assessment of left-ventricular function in patients with suspected heart failure could lead to more successful treatment. An estimated 120,000 patients are admitted to hospital every year in the UK with heart disease. The disorder can be effectively treated if accurately diagnosed; however, accurate data for prevalence rates for heart failure due to various causes, and for left-ventricular systolic dysfunction (LVSD) in all adults are unavailable. Richard Hobbs and colleagues from the University of Birmingham, UK, did a population stu
NEW DRUG TREATMENT COULD PROVIDE LONG-TERM BENEFIT FOR HEART-ATTACK PATIENTS (p 1385)
Patients with acute myocardial infarction (heart attack), complicated by left-ventricular systolic dysfunction, could benefit from the ß-blocker carvedilol, conclude authors of a study in this week's issue of THE LANCET. In a randomised, placebo-controlled trial, this drug reduced the frequency of death from all causes, death from cardiovascular disease, and prevented the recurrence of non-fatal heart attacks. The beneficial effects of ß-blockers on long-term outcome after acute myocardial infarction were shown before the introduction of thrombolysis and angiotensin-converting-enzyme (ACE) inhibitors. Generally, the patients recruited to these trials were at low risk: few had heart fai
More Systolic Dysfunction Current Events and Systolic Dysfunction News Articles
| © 2009 BrightSurf.com |